Dr. Reddy’s Launches Oral Semaglutide Biosimilar Obeda in India
Market Entry and Clinical Specifications Dr. Reddy’s Laboratories, a leading pharmaceutical giant based in Hyderabad, announced the commercial launch of Obeda, an oral biosimilar version of semaglutide, in India this week. The medication, designed to treat type 2 diabetes, is available in 3 mg, 7 mg, and 14 mg strengths and is intended for once-daily…